Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × Lenalidomide × 30 days × Clear all

NCT06149286 2026-04-13

OLYMPIA-5

Phase 3 Recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04903197 2026-04-01

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06793189 2026-03-24

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma